Theialife Announces Positive Type C Meeting with FDA for ND10 in Progressive Myopia
Company and Agency align on pivotal program design, endpoint strategy and study duration, providing clear path forward for ND10 development
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


